by GlobeNewsWire | Dec 16, 2015 | Globe Newswire
PHILADELPHIA, Dec. 16, 2015 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN), today announced the initiation of a research program to evaluate the use of TARGTEPOTM alone or in combination with iron restriction to ameliorate erythropoiesis in Beta Thalassemia...
by GlobeNewsWire | Oct 22, 2015 | Globe Newswire
Acquired Phase 2-Ready CNS asset, NFC-1 First of pipeline of potential programs from CHOP collaboration Results of Phase 1 GREAT trial to be presented at American Academy of Child and Adolescent Psychiatry (AACAP) meeting Completed Successful Public Offering for $46M...
by GlobeNewsWire | Oct 12, 2015 | Globe Newswire
PHILADELPHIA, Oct. 12, 2015 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN) today announced the completion of an underwritten public offering of 7,078,250 shares of its common stock, including 923,250 shares sold pursuant to the full exercise of an option...
by GlobeNewsWire | Oct 1, 2015 | Globe Newswire
PHILADELPHIA, Oct. 1, 2015 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN) today announced the pricing of 6,155,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $6.50 per share. In connection...
by GlobeNewsWire | Sep 30, 2015 | Globe Newswire
PHILADELPHIA, Sept. 30, 2015 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no...